# Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

> **NCT03840343** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 2 (actual)

## Conditions studied

- Diabetic Kidney Disease
- Diabetic Nephropathies
- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Type 1
- Chronic Kidney Disease
- Diabetic Nephropathy Type 2
- Kidney Failure
- Kidney Insufficiency

## Interventions

- **BIOLOGICAL:** Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose
- **BIOLOGICAL:** Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose

## Key facts

- **NCT ID:** NCT03840343
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-23
- **Primary completion:** 2020-08-04
- **Final completion:** 2020-08-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Principal Investigator relocation
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03840343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03840343, "Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03840343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*